Fetch.ai leads rally of major AI-related tokens as Nvidia becomes world's most valuable company
Fetch.ai has spearheaded a number of significant gains made by major AI-related cryptocurrency tokens in the past 24 hours, rallying over 25%.The rally comes in the wake of Nvidia becoming the world’s most valuable company.
Fetch.ai FET +16.74% has spearheaded significant gains made by major AI-related cryptocurrency tokens in the past 24 hours, with the rally coming in the wake of Nvidia becoming the world's most valuable company.
Fetch.ai (FET) saw the largest rise of over 25%, Bittensor (TAO) climbed by over 19%, Render (RNDR) jumped by over 13%, while NEAR Protocol (NEAR) and Internet Computer (ICP) saw gains under 10% each, according to CoinGecko data .
The artificial intelligence sector is currently the hottest corner in both traditional and crypto markets, according to Nansen.ai analyst Edward Wilson. Wilson highlighted that the rally of AI-related tokens comes after U.S. computer chip manufacturer Nvidia claimed the title of the world's most valuable company, as its share price hit an all-time high of over $136 by close of trade on Tuesday.
"It should come as no surprise that on the back of Nvidia becoming the world's most valuable company that AI tokens like NEAR, RNDR and others are rallying. Both of these tokens are up around 300% in the past year, compared to ether at just over 100% during the same time period, showing high market interest in this sector," Wilson told The Block.
However, YouHodler Risk Manager Sergei Gorev urged caution regarding the latest AI-related rally, suggesting that more clarity is needed as there could currently be more hype to valuations than substance.
"As for the quotes of NVIDIA shares, we consider the stock’s recent dynamics as a result of the market’s overreaction on prospects that are not yet fully clear. The narrative of 'creating something new' has always caused hype in the market, whether it's 3D printers or EVs, etc. And now it’s about the hype around AI," Gorev told The Block.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
